Sagimet Biosciences Inc (SGMT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.94+0.18%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SGMT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance denifanstat into a registrational Phase 3 clinical trial in moderate to severe acne patients in the U.S. in the second half of 2026, contingent on regulatory consultation and IND clearance.
Stated as a priority in 3 of last 3 quarters. Management consistently plans to initiate a Phase 3 clinical trial of denifanstat in moderate to severe acne in the U.S. in the second half of 2026, contingent on regulatory consultation and IND clearance. This aligns with the repeated guidance and no contradictory updates, indicating the company is maintaining focus on this milestone.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026”
“Targeting second half of 2026 to initiate a Phase 3 clinical trial of denifanstat in moderate to severe acne in the U.S.”
“Plan to advance denifanstat into a Phase 3 clinical trial in moderate to severe acne patients for the US in 2H 2026, contingent on consultation with regulatory authorities”
Preserve cash, cash equivalents, and marketable securities to fund current operations through 2028, including the Phase 3 denifanstat trial and NDA submission.
Stated as a priority in 3 of last 3 quarters. Cash, cash equivalents and marketable securities increased significantly from $104.5 million at 2026-Q1 to $257.6 million at 2026-Q2, primarily due to a $175 million equity financing in April 2026. Management expects this strong cash position to fund operations through 2028, including the Phase 3 denifanstat trial, indicating delivery on this priority.
“Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026, expected to fund current operations through 2028”
“Existing cash and proceeds from $175 million equity offering expected to fund programs through 2028”
“Cash, cash equivalents and marketable securities were $104.5 million as of March 31, 2026”
Continue clinical development of TVB-3567, including ongoing Phase 1 trial and planned Phase 2 trial in moderate to severe acne patients in 2H 2026, subject to regulatory feedback.
Stated as a priority in 3 of last 3 quarters. The Phase 1 clinical trial of TVB-3567 has been ongoing since June 2025, with management planning to initiate a Phase 2 trial in moderate to severe acne patients in the second half of 2026, subject to regulatory feedback. This consistent focus and ongoing trial activity indicate progress in advancing this clinical program.
“First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing”
“Phase 1 clinical trial of TVB-3567 ongoing; plan to initiate Phase 2 trial in 2H 2026 subject to regulatory feedback”
“TVB-3567 received IND clearance in March 2025; Phase 1 clinical trial initiated in June 2025”
Sagimet plans to start a Phase 3 clinical trial for denifanstat in moderate to severe acne patients in the U.S. in the second half of 2026.
Over the trailing year it converted 0.84x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.